Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
Mining of OA alert signals using the openFDA database provides supplementary information on AEs not included in the drug label. Clinical attention should be focused on common, strong-signal, and label-unmentioned AEs to optimise medication regimens and control risks in clinical use.
Authors
- Yuezhen Zhang
- Jingfang Ye
- Qiying Chen (ORCID: https://orcid.org/0000-0003-3118-2129)
- Tianyu Chen (ORCID: https://orcid.org/0009-0000-4930-7685)
- Ting Liu (ORCID: https://orcid.org/0000-0002-5824-3975)
- Yuzhu Wu
Institutions
- Fujian Medical University (CN)
- Quanzhou Normal University (CN)
- Quzhou College of Technology (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1186/s13023-025-03715-2
- Citations
- 3
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 4.88